Agios Pharmaceuticals Inc (NASDAQ: AGIO) has reported a loss for its first fiscal quarter (ending March 31) of $-1.45 versus a loss $-1.47 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $-6.32 versus $-3.97 for the same period a year ago.
Recent Price Action
Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock closed at $34.58 on 5/2/24 after a large increase of 2.7%. NORMAL trading volume accompanied the advance. The stock has risen 9.2% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
AGIO is expected to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Agios Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Agios Pharmaceuticals has a poor Appreciation Score of 15 but a slightly positive Power Rating of 68, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment